Mary Jo Fidler to Cohort Studies
This is a "connection" page, showing publications Mary Jo Fidler has written about Cohort Studies.
Connection Strength
0.225
-
Prevalence and predictors of neoadjuvant therapy for stage IIIA non-small cell lung cancer in the National Cancer Database: importance of socioeconomic status and treating institution. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):303-12.
Score: 0.082
-
In Patients with Membranous Lupus Nephritis, Exostosin-Positivity and Exostosin-Negativity Represent Two Different Phenotypes. J Am Soc Nephrol. 2021 03; 32(3):695-706.
Score: 0.033
-
Heterogeneity in the clinical presentation, diagnosis, and treatment initiation of p16-positive oropharyngeal cancer. Am J Otolaryngol. 2019 Sep - Oct; 40(5):626-630.
Score: 0.029
-
Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer. Am J Clin Oncol. 2015 Dec; 38(6):605-9.
Score: 0.023
-
Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response. J Thorac Oncol. 2015 Oct; 10(10):1475-80.
Score: 0.023
-
Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis. 2012 Jun; 59(6):786-94.
Score: 0.018
-
Myeloproliferative neoplasms cause glomerulopathy. Kidney Int. 2011 Oct; 80(7):753-9.
Score: 0.017